Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 1:2:29.
doi: 10.3389/fsurg.2015.00029. eCollection 2015.

Results from a First-in-Human Trial of a Novel Vascular Sealant

Hans-Joachim Florek  1 , Jan Brunkwall  2 , Karl-Heinz Orend  3 , Ian Handley  4 , John Pribble  5 , Ronald Dieck  4
Affiliations

Results from a First-in-Human Trial of a Novel Vascular Sealant

Hans-Joachim Florek et al. Front Surg. .

Abstract

Background: Suture hole bleeding from synthetic grafts presents a hemostatic challenge. The designs of many vascular sealants are not optimal (non-adherence to wet surfaces, excessive swelling, inflexible). PreveLeak™ (formerly ArterX ((®)) ) is a polyaldehyde-bovine serum albumin-based sealant whose efficacy, safety, and performance were evaluated in this first-in-human study.

Materials and methods: A prospective, single-arm, multicenter study was performed in patients undergoing open vascular reconstructions with prosthetic grafts. Sealant was applied to the suture line after completion of the anastomosis. The primary endpoint was the incidence of immediate sealing (without clinically significant bleeding) upon clamp release. Secondary endpoints were time to sealing, safety, and assessment of product performance.

Results: Fifty-six anastomoses were performed in 32 patients. Grafts were Dacron (66% of sites), polytetrafluoroethylene (PTFE; 32%), or both Dacron and PTFE (2%). The femoral artery was the most common site of anastomosis (41% of sites). Immediate sealing after clamp release was achieved at all anastomoses (100%); 93% had no bleeding and 7% had oozing. No rebleeding occurred during 10 min of observation. The three most common adverse events were graft or bypass occlusion (n = 5 patients), infection (n = 4), and seroma (n = 3); none were device related. The sealant was considered easy to apply, quickly forming a soft gel, and adhering to tissue and grafts.

Conclusion: PreveLeak effectively sealed anastomotic suture lines during vascular reconstruction procedures and was considered easy to use. Adverse events were consistent with those commonly observed in patients undergoing surgical procedures. These results provided the support for conducting a larger controlled clinical trial.

Keywords: albumin; efficacy evaluation; hemostasis; polyaldehyde; safety; surgical sealant; vascular surgery.

PubMed Disclaimer

References

    1. Carney WI, Jr, Lilly MP. Intraoperative evaluation of PTFE, Dacron and autologous vein as carotid patch materials. Ann Vasc Surg (1987) 1:583–6.10.1016/S0890-5096(06)61445-3 - DOI - PubMed
    1. McCready RA, Siderys H, Pittman JN, Herod GT, Halbrook HG, Fehrenbacher JW, et al. Delayed postoperative bleeding from polytetrafluoroethylene carotid artery patches. J Vasc Surg (1992) 15:661–3.10.1016/0741-5214(92)90012-W - DOI - PubMed
    1. Patel PA, Fleisher LA. Aspirin, clopidogrel, and the surgeon. Adv Surg (2014) 48:211–22.10.1016/j.yasu.2014.05.005 - DOI - PubMed
    1. Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br J Surg (2014) 101:742–9.10.1002/bjs.9485 - DOI - PubMed
    1. Shander A, Kaplan LJ, Harris MT, Gross I, Nagarsheth NP, Nemeth J, et al. Topical hemostatic therapy in surgery: building the knowledge and practice gap. J Am Coll Surg (2014) 219:570–9.10.1016/j.jamcollsurg.2014.03.061 - DOI - PubMed